Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including ...

Novo Nordisk A/S rose the most in a month after an experimental shot delivered as much as 22% weight loss in an early-stage ...

Novo Nordisk A/S, GE HealthCare Technologies Inc. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...